Ann: FSGS Study, Partnering & Commercialisation Investor Briefing, page-15

I'm glad the study case they have got is Neuren. Makes you think that if they are confident that they will negotiate similar terms or an even better one.

Not cross promoting here but the resemblance is not too far apart. We are heading into pivotal results and have finance up to half, perhaps slightly less than half but no matter, still a statistically powered Phase 3.

The orphan drug market is of similar size, I have a feeling FSGS might be slightly smaller in potential since NEU's deal was for all of a drug and they are first to market, but nonetheless FSGS seems bigger than Retts.

Similar to NEU, ideally I would value a backended deal + Upfront payments to cover the cost of trial remaining - and by the looks of things this seems to be what they are going for too.

If it all comes together for DXB, it would be such an exciting company. In similar ways, to NEU, DXB has a trump card in its pipeline and still plenty to roll out. This FSGS trial will be make or break - what a pivotal time and to think we have a partner in the wings is a good, key component to the puzzle. Just hope they came to the table with some fairness, and not a low ball offer.